0001209191-21-027460.txt : 20210419
0001209191-21-027460.hdr.sgml : 20210419
20210419210018
ACCESSION NUMBER: 0001209191-21-027460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210415
FILED AS OF DATE: 20210419
DATE AS OF CHANGE: 20210419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chiang Kyle
CENTRAL INDEX KEY: 0001831341
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38707
FILM NUMBER: 21836038
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVENUE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664106
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471514975
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-245-0399
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-15
0
0001664106
LogicBio Therapeutics, Inc.
LOGC
0001831341
Chiang Kyle
C/O LOGICBIO THERAPEUTICS, INC.
65 HAYDEN AVE, FLOOR 2
LEXINGTON
MA
02421
0
1
0
0
Chief Operating Officer
Common Stock
2021-04-15
4
M
0
9360
A
26364
D
Common Stock
2021-04-16
4
S
0
2977
5.73
D
23387
D
Restricted Stock Units
2021-04-15
4
M
0
9360
0.00
D
Common Stock
9360
0
D
Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
Relates to shares sold at a weighted average price of $5.73 per share to cover tax withholding obligations in connection with the vesting of RSUs. Shares were sold in multiple transactions at prices ranging from $5.68 to $5.89, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the RSUs vested on April 15, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.
/s/ Jonathan Quick, as attorney-in-fact
2021-04-19